TRINOVA-1：卵巣がん、原発性腹膜がん、卵管がんの治療として、AMG 386またはプラセボと週1回のパクリタキセル化学療法を併用する試験

基本情報

NCT ID: NCT01204749
ステータス: 完了
試験のフェーズ: 第3相
試験タイプ: 介入
目標被験者数: 919
治験依頼者名: Amgen

概要

The purpose of this study is to determine if treatment with paclitaxel plus AMG 386 is superior to paclitaxel plus placebo in women with recurrent partially platinum sensitive or resistant epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer. AMG 386 is a man-made medication that is designed to stop the development of blood vessels in cancer tissues. Cancer tissues rely on the development of new blood vessels, a process called angiogenesis, to obtain a supply of oxygen and nutrients to grow.

対象疾患

Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cancer

介入

AMG 386(DRUG)

AMG 386 Placebo(DRUG)

Paclitaxel(DRUG)

依頼者（Sponsor）

アムジェン株式会社(INDUSTRY)